Market Size of Lacrimal Duct Stent Tube Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Lacrimal Duct Stent Tube Market Analysis
The lacrimal duct stent tube market is anticipated to record a CAGR of 5.2% over the forecast period.
The COVID-19 pandemic presented significant hurdles for the healthcare sector. Since the majority of surgical procedures were considered to be non-urgent, all outpatient consultations were delayed or restricted during the COVID-19 pandemic to lower the danger of viral transmission. Thus, the lacrimal duct stent market was adversely impacted during the pandemic. However, it is expected to gain traction in the post-pandemic era due to the resumption of surgical procedures.
Certain factors that are driving the market include the increasing patient pool for nasolacrimal duct obstruction and rising demand for treatments with minimal invasions and better success rates. Nasolacrimal duct obstruction (NLDO) or dacryostenosis is the most common disorder of the lacrimal system. According to the August 2022 updated report, published by the NCBI, congenital nasolacrimal duct obstruction may occur in 3-6% of newborns, while it occurs bilaterally in 20% of newborns. There is a high rate of spontaneous resolution of congenital nasolacrimal duct obstruction, with approximately 70% of affected children being free of the symptoms by 3 months of age, and over 90% recovering by their first birthday. However, infants at increased risk for this condition include those with trisomy 21, ectrodactyly-ectodermal dysplasia-cleft lip/palate (EEC) syndrome, branchiooculofacial syndrome, CHARGE (coloboma, heart anomaly, choanal atresia, and retardation, genital, and ear anomalies) syndrome, and Goldenhar syndrome. Hence, the rising prevalence of such health conditions is expected to drive the market over the forecast period.
New studies on lacrimal stent tubes help expand the applications for various conditions, which is expected to boost the market's growth over the forecast period. For instance, as per the study published by the European Journal of Ophthalmology in December 2021, lacrijet monocanalicular stent intubation has a high rate of success, shortens the surgical time, and has a low rate of complications in children with congenital nasolacrimal duct obstruction. Hence, the new studies on lacrimal stent tubes expand the indications and provide the safety and efficacy of the stents, which may drive the market over the forecast period.
However, complications associated with stent tubes are likely to hinder the growth of the market over the forecast period.
